MedTrace Logo

Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study

NCT05885594 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-11-26

No results posted yet for this study

Summary

Study to enroll up to 90 individuals, those with an alcohol use disorder (AUD) (up to n=60) and non-dependent healthy volunteers (HV) (up to n=30).

PET/CT imaging will be used to evaluate brain and whole-body inflammation using the investigational radiotracer \[18F\]NOS.

All participants will have one \[18F\]NOS positron emission tomography/ computed tomography (PET/CT) scan performed.

Conditions

Interventions

DRUG

[18F]NOS

\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.

Sponsors & Collaborators

Principal Investigators

  • Jacob Dubroff, MD, PhD · Perelman School of Medicine, Dept. of Radiology

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2027-03-15
Completion
2027-03-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05885594 on ClinicalTrials.gov